Lung Fibrosis after COVID-19: Treatment Prospects
Review
[키워드] antifibrotic therapy
Asymptomatic individuals
caused
clinical trial
Community
Complication
complications
contagious infection
COVID
COVID-19
death
deupirfenidone
diffusing
drug candidates
effective therapy
effort
fibrosis
fraction
impairment
incidence
incidence rate
interstitial
lung
lung damage
Lung fibrosis
Lung pathology
moderate
morbidity
MOST
Nintedanib
Novel coronavirus
pathogen
Patient
Pirfenidone
progression
pulmonary damage
pulmonary fibrosis
reduction in
rehabilitation
remained
respiratory complication
respiratory manifestation
SARS patient
SARS-CoV-2
the disease
the patient
These data
treamid
Treatment
Vaccine
Vascular
[DOI] 10.3390/ph14080807 PMC 바로가기 [Article Type] Review
[DOI] 10.3390/ph14080807 PMC 바로가기 [Article Type] Review